Sept. 11, 2025 — Naitive Technologies, a medical technology company developing AI-driven software to reimagine orthopedic care, has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its flagship product, OsteoSight. OsteoSight is designed to enable orthopedic practices to take a proactive role in osteoporosis management, supporting earlier interventions, and new growth opportunities for practices. "The FDA's clearance of OsteoSight technology represents a critical step forward in orthopedics. "We are proud that OsteoSight has received FDA 510(k) clearance," said Dr. Will Briggs, CEO of Naitive. With FDA clearance, Naitive is advancing commercial partnerships to bring OsteoSight into orthopedic practices across the US.